EUCTR2007-004310-14-BE
Active, not recruiting
Phase 1
Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II study
CHU-ULG0 sites120 target enrollmentDecember 10, 2007
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- CHU-ULG
- Enrollment
- 120
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient eligibility criteria
- •1\. Male or female of any age.
- •2\. Previous allogeneic transplantation or autologous transplantation (for part 2 only) of HSC at any time before.
- •3\. Informed consent given by donor or his/her guardian if of minor age.
- •4\. Additional criteria for each part of the protocol:
- •Part 1: MSC for steroid\-refractory grade II\-IV acute GVHD
- •\- Acute GVHD refractory to mPDN 2 mg/kg/day or equivalent
- •Part 2: MSC for poor graft function (PGF)
- •\- Cytopenia in 2 or 3 lineages:
- •\- Cytopenia duration \= 2 weeks beyond day 28 after autologous HCT, or day 42 Part 3: MSC \+ DLI for poor donor T\-cell chimerism
Exclusion Criteria
- •1\. HIV positive.
- •2\. Active uncontrolled infection at time of scheduled MSC infusion.
- •3\. Relapsing or progressing malignancy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Withdrawn
Phase 2
Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II studymesenchymale stamcellen bij acute GvHD of onvoldoende functionerende greffeacute GvHDrejection1002432410018865NL-OMON31471Academisch Ziekenhuis Maastricht10
Active, not recruiting
Not Applicable
Therapeutic effect of mesenchymal cells in patients suffering from a disease characterized by a severe inflammation and/or in whom the immune system attacks their own tissues.Crohn's diseaseMedDRA version: 14.0Level: LLTClassification code 10011402Term: Crohn's disease (colon)System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: HLGTClassification code 10003816Term: Autoimmune disordersSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 14.0Level: PTClassification code 10064147Term: Gastrointestinal inflammationSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2011-005966-39-BECHU-ULg20
Recruiting
Phase 1
Cell therapy with use of mesenchymal stem cells in infertile women with Thin EndometriumIRCT20230222057500N1Tehran University of Medical Sciences10
Active, not recruiting
Not Applicable
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.Therapeutic area: Body processes [G] - Cell Physiological Phenomena [G04]EUCTR2012-002553-38-ESItziar Astigarraga Aguirre
Active, not recruiting
Not Applicable
Application of Mesenchymal Stem Cells and full of plasma in the management of the burn wound in patients with large burn injury - Stem CellsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2012-001596-36-ESMIGUEL CASARES FERNÁNDEZ-ALVÉS